Agoraphobia

Innerworld Announces Singer-Songwriter & Mental Health Expert Jewel as Co-Founder and Chief Strategy Officer

Retrieved on: 
Tuesday, February 21, 2023
PC, Robinson, IPad, Psychology, Vanderbilt, Oculus Quest, Depression, Vanderbilt University, Research, Agoraphobia, Cognitive behavioral therapy, CBT, Anxiety, Meditation, Student, IPhone, Trauma, Habit, CBI, Eating disorder, Doctor of Philosophy, Mental health, Nursing, Innerworld, Mac

NASHVILLE, Tenn., Feb. 21, 2023 /PRNewswire/ -- Today, the revolutionary mental health platform Innerworld announces multi-platinum, Grammy-nominated singer-songwriter Jewel as Co-Founder and Chief Strategy Officer. The longtime mental health advocate joins Innerworld's Founder and CEO Noah Robinson to build the largest community in the metaverse for mental health support. To meet the tremendous consumer demand for mental health intervention, Innerworld offers peer-to-peer support groups with expert guides trained in Cognitive Behavioral Immersion™ providing evidence-based tools during live groups in social virtual worlds.  For the first time, scalable peer-to-peer support is accessible on demand in immersive, social virtual worlds where people can interact as anonymous avatars. During special live group sessions, starting today, Jewel will teach her life-changing tools as an avatar inside of Innerworld. Innerworld's freemium platform hosts over 100 weekly events that can be accessed from any device including the Meta Quest or on Mac, PC, iPad and iPhone.

Key Points: 
  • NASHVILLE, Tenn., Feb. 21, 2023 /PRNewswire/ -- Today, the revolutionary mental health platform Innerworld announces multi-platinum, Grammy-nominated singer-songwriter Jewel as Co-Founder and Chief Strategy Officer.
  • The longtime mental health advocate joins Innerworld's Founder and CEO Noah Robinson to build the largest community in the metaverse for mental health support.
  • It's simply not possible and with today's mental health crisis, we are beyond the luxury of merely raising awareness around mental health," says Jewel.
  • We are building towards the future of mental health 3.0, where everyone can access mental health help."

VA awards OxfordVR $500,000 in Mission Daybreak grand challenge to reduce Veteran suicides

Retrieved on: 
Thursday, February 16, 2023
Cognitive behavioral therapy, DSM-IV codes, Therapy, Anxiety, VR, PTSD, Patient, Bipolar disorder, U.S. Department of Veterans Affairs, Office of Inspector General, Family, Psychosis, Agoraphobia, FDA, Veterans Health Administration, Virtual reality, GameChanger, Real estate, Veteran

NASHVILLE, Tenn., Feb. 16, 2023 /PRNewswire/ -- The U.S. Department of Veterans Affairs has named OxfordVR as a winner in Mission Daybreak — a $20 million challenge designed to help VA develop new suicide prevention strategies for Veterans. As a third-place award winner, OxfordVR, which recently came under the BehaVR umbrella, will receive $500,000 to further support the company's work in developing virtual reality (VR) solutions to address mental and behavioral health challenges in support of Veterans.

Key Points: 
  • As a third-place award winner, OxfordVR, which recently came under the BehaVR umbrella, will receive $500,000 to further support the company's work in developing virtual reality (VR) solutions to address mental and behavioral health challenges in support of Veterans.
  • OxfordVR was the first to successfully automate psychological therapy in VR for patients with mental illness through its immersive, VR delivered gameChange treatment, which targets the intense fears and anxieties that prevent people from fully participating in everyday activities.
  • The company is currently working to demonstrate the treatment's effectiveness across a broad and diverse set of indications and is partnering with the VA to demonstrate its effectiveness in helping home-bound veterans re-integrate with their communities and the VA Medical System.
  • "If this work helps support even one veteran and family, it's a win - but we're excited by the opportunity to make a broader impact on Veteran Suicide."

Hunt A Killer Reveals New Mystery Subscription Box Game, Short Film, Unexplained Mysteries Series, and more for the Holiday Season

Retrieved on: 
Tuesday, November 15, 2022
Family, Fear, Taste, City, Friends, Snow, Hunting, Crime, YouTube, Faire, VP, Coffee, Creativity, Entertainment, Whaling, Agoraphobia, Mystery

BALTIMORE, Nov. 15, 2022 /PRNewswire/ -- When the cold winter winds blow, the snow piles up, and the fire is crackling, then you know mystery is afoot. Hunt A Killer, the immersive entertainment company, has just announced multiple new mysteries including its new subscription box season titled Renfaire Regicide, releasing in December. With this release, the last subscription box season, Murder On Ice, will convert to a complete episodic box set. Additionally, new free content including an original short film, a series of shorts on unexplained mysteries, and more is launching on the company's website - bringing a whole new way for people to engage and join in on the experiences that Hunt A Killer offers.

Key Points: 
  • Hunt A Killer , the immersive entertainment company, has just announced multiple new mysteries including its new subscription box season titled Renfaire Regicide, releasing in December.
  • With this release, the last subscription box season, Murder On Ice , will convert to a complete episodic box set.
  • Hunt A Killer has announced multiple new mysteries including its new subscription box season titled Renfaire Regicide.
  • "Our team is continuing to put out unique and thrilling stories, including our new subscription box season, free original short film, mystery series, and more.

OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)

Retrieved on: 
Wednesday, April 6, 2022
Software, Hardware, General Health, Health, Mental Health, Technology, Other Technology, Other Health, Oxford Health NHS Foundation Trust, Cognitive behavioral therapy, Family, Therapy, CBT, University, Delusion, Mental health, Union, Clinical trial, University of Oxford, Agoraphobia, Friends, The Lancet, Psychosis, Lists of diseases, Paranoia, Research, Patient, Hallucination, Schizophrenia, Quality of life, Virtual reality, Technology, Safety, GameChanger, Anxiety, Department, Trust law, Depression, Education, Pharmaceutical industry, Medicine, VR

Users are guided by a virtual coach instead of a real-life therapist, allowing the treatment to reach many more patients.

Key Points: 
  • Users are guided by a virtual coach instead of a real-life therapist, allowing the treatment to reach many more patients.
  • The technology, called gameChangeVRTM is a 6 week, automated, VR treatment that delivers cognitive behavioral therapy (CBT) inside safe, immersive, virtual scenarios.
  • OxfordVR is a digital therapeutics company that develops evidence-based immersive treatments using virtual reality for serious mental illness.
  • OxfordVR is dedicated to improving world class access to mental health, automating gold-standard treatments like cognitive behavioral therapy (CBT).

One Mind Announces Jewel as Next One Mind Champion and Advisory Board Member

Retrieved on: 
Thursday, October 7, 2021
Mindfulness, Mental health, Brain, Facebook, 2021–22 NCAA football bowl games, American Music Awards, Mind, Psychiatry, MTV Video Music Awards, Saturday Night Live, Electronic oscillator, Gold, Time, 1989 NBA Finals, Country music awards, Time (magazine), Rolling Stone, TIME, World Mental Health Day, Kroger, Brown University, Depression, Seoul Music Awards, Agoraphobia, Hope, One Mind, NBA Finals, Super Bowl, Awareness, Pope, Partnership, Human, Billboard Music Awards, Mental, Pharmaceutical industry

RUTHERFORD, Calif., Oct. 7, 2021 /PRNewswire/ -- Leading mental health and brain research nonprofit One Mind today announced renowned singer-songwriter and multi-platinum recording artist Jewel as a One Mind Champion and Advisory Board Member.

Key Points: 
  • RUTHERFORD, Calif., Oct. 7, 2021 /PRNewswire/ -- Leading mental health and brain research nonprofit One Mind today announced renowned singer-songwriter and multi-platinum recording artist Jewel as a One Mind Champion and Advisory Board Member.
  • I'm thrilled to be partnering with One Mind to continue to be a voice of hope within the crucial conversation around mental health."
  • One of Jewel's first efforts as a One Mind Champion and Advisory Board Member is to launch a World Mental Health Day fundraiser on Sunday, October 10, 2021 to support One Mind and the Inspiring Children Foundation.
  • Jewel will also serve as an advisor on One Mind's Lived Experience Advisory Board and Brandon Staglin will serve on the advisory board of the Inspiring Children Foundation.

Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)

Retrieved on: 
Monday, September 14, 2020
Phobias, Psychiatry, RTT, Anxiety disorders, Psychiatric diagnosis, Abnormal psychology, Social anxiety disorder, Agoraphobia, Specific phobia, Anxiolytic, Patent

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.

Key Points: 
  • NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.
  • The issued claims cover a formulation and method of using SLS-002 to treat patients experiencing anxiety due to phobic disorders such as: Specific Phobia, Agoraphobia, and Social Phobia.
  • Additionally, Seelos has received a Notice of Allowance from the Japanese Patent Office (Japanese patent application number 2018-124196) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE.
  • The allowed claims cover a formulation and method of using SLS-002 to prevent anxiety in patients prior to medical or dental procedures.